<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00736333</url>
  </required_header>
  <id_info>
    <org_study_id>P04878</org_study_id>
    <nct_id>NCT00736333</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED)</brief_title>
  <official_title>Observational Program of Caelyx in MBC - Prevention and Treatment of PPE and Infusion Reactions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the safety and tolerability of Caelyx used for the treatment of
      metastatic breast cancer (MBC), focusing on infusion reaction and palmar-plantar
      erythrodysesthesia (PPE).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients selected by investigator according to clinical routine
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Infusion Reactions (IR)</measure>
    <time_frame>Day 1 up to Week 24</time_frame>
    <description>Infusion reaction was defined as an allergic reaction or anaphylactoid reaction characterized by shortness of breath, hypotension, back pain, chest pain, chills, flush, sweating, fever, nausea, dizziness, rash, pruritis, or tachycardia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Taking Premedication for Prevention of IR</measure>
    <time_frame>Day 1, immediately prior to receiving first dose of pegylated liposomal doxorubicin</time_frame>
    <description>Premedications for prevention of IR included corticosteroids, serotonin-3 receptor antagonists (anti-emetics), histamine-1 receptor blockers, and histamine-2 receptor blockers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Pre-existing Allergic Conditions Who Experienced an IR</measure>
    <time_frame>Cycles 1 &amp; 3 (Week 4 &amp; Week 12)</time_frame>
    <description>Allergic conditions included food allergies, drug allergies, allergic rhinitis, histamine allergy, neurodermatitis, and chronic idiopathic urticaria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Occurrences of Palmar-plantar Erythrodysesthesia (PPE)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>PPE was defined as a dermatological adverse event characterized by swelling, pain, edema, erythema, desquamation, that may have ultimately resulted in fissuring and ulceration, involving fingers, toes, palms, plantar aspects of the feet, and other pressure-sensitive areas of the skin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Times Premedications Were Given for Prevention of PPE</measure>
    <time_frame>Day 1 up to 24 weeks</time_frame>
    <description>Pre-medications given included oral dexamethasone, vitamin B6, and other not clearly defined medications.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Complete Response (CR) or Partial Response (PR)</measure>
    <time_frame>Day 1 up to 24 weeks</time_frame>
    <description>CR and PR were documented according to the clinical standards of each site.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">167</enrollment>
  <condition>Breast Neoplasm</condition>
  <arm_group>
    <arm_group_label>Pegylated Liposomal Doxorubicin</arm_group_label>
    <description>Subjects with metastatic breast cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Liposomal Doxorubicin</intervention_name>
    <description>Pegylated Liposomal Doxorubicin (Caelyx) 50 mg/m^2, given for up to 6 cycles</description>
    <arm_group_label>Pegylated Liposomal Doxorubicin</arm_group_label>
    <other_name>SCH 200746</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with metastatic breast cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with metastatic breast cancer

        Exclusion Criteria:

          -  History of hypersensitivity to Caelyx or its components

          -  Women who are pregnant or breast-feeding

          -  Patients with severe myelosuppression
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Austria</country>
  </removed_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2008</study_first_submitted>
  <study_first_submitted_qc>August 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2008</study_first_posted>
  <results_first_submitted>June 13, 2011</results_first_submitted>
  <results_first_submitted_qc>June 13, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 7, 2011</results_first_posted>
  <last_update_submitted>October 31, 2014</last_update_submitted>
  <last_update_submitted_qc>October 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pegylated Liposomal Doxorubicin</title>
          <description>Pegylated liposomal doxorubicin 50 mg/m^2 given every 4 weeks for up to 6 cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did Not Receive Drug or Not Documented</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Data Missing</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Tumor Progression</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pegylated Liposomal Doxorubicin</title>
          <description>Pegylated liposomal doxorubicin 50 mg/m^2 given every 4 weeks for up to 6 cycles</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age was calculated for the intent-to-treat (ITT) population only (those who received at least one dose of study medication).</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Gender information was available only for the ITT population.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Infusion Reactions (IR)</title>
        <description>Infusion reaction was defined as an allergic reaction or anaphylactoid reaction characterized by shortness of breath, hypotension, back pain, chest pain, chills, flush, sweating, fever, nausea, dizziness, rash, pruritis, or tachycardia.</description>
        <time_frame>Day 1 up to Week 24</time_frame>
        <population>Safety population (those who received at least one dose of study medication)</population>
        <group_list>
          <group group_id="O1">
            <title>Pegylated Liposomal Doxorubicin</title>
            <description>Pegylated liposomal doxorubicin 50 mg/m^2 given every 4 weeks for up to 6 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infusion Reactions (IR)</title>
          <description>Infusion reaction was defined as an allergic reaction or anaphylactoid reaction characterized by shortness of breath, hypotension, back pain, chest pain, chills, flush, sweating, fever, nausea, dizziness, rash, pruritis, or tachycardia.</description>
          <population>Safety population (those who received at least one dose of study medication)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Complete Response (CR) or Partial Response (PR)</title>
        <description>CR and PR were documented according to the clinical standards of each site.</description>
        <time_frame>Day 1 up to 24 weeks</time_frame>
        <population>Intent-to-treat (those who received at least one dose of study medication)</population>
        <group_list>
          <group group_id="O1">
            <title>Pegylated Liposomal Doxorubicin</title>
            <description>Pegylated liposomal doxorubicin 50 mg/m^2 given every 4 weeks for up to 6 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Response (CR) or Partial Response (PR)</title>
          <description>CR and PR were documented according to the clinical standards of each site.</description>
          <population>Intent-to-treat (those who received at least one dose of study medication)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Taking Premedication for Prevention of IR</title>
        <description>Premedications for prevention of IR included corticosteroids, serotonin-3 receptor antagonists (anti-emetics), histamine-1 receptor blockers, and histamine-2 receptor blockers.</description>
        <time_frame>Day 1, immediately prior to receiving first dose of pegylated liposomal doxorubicin</time_frame>
        <population>Safety population (those who received at least one dose of study medication)</population>
        <group_list>
          <group group_id="O1">
            <title>Pegylated Liposomal Doxorubicin</title>
            <description>Pegylated liposomal doxorubicin 50 mg/m^2 given every 4 weeks for up to 6 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Taking Premedication for Prevention of IR</title>
          <description>Premedications for prevention of IR included corticosteroids, serotonin-3 receptor antagonists (anti-emetics), histamine-1 receptor blockers, and histamine-2 receptor blockers.</description>
          <population>Safety population (those who received at least one dose of study medication)</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Corticosteroids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotonin-3 receptor antagonists (anti-emetics)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Histamine-1 receptor blockers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Histamine-2 receptor blockers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Pre-existing Allergic Conditions Who Experienced an IR</title>
        <description>Allergic conditions included food allergies, drug allergies, allergic rhinitis, histamine allergy, neurodermatitis, and chronic idiopathic urticaria.</description>
        <time_frame>Cycles 1 &amp; 3 (Week 4 &amp; Week 12)</time_frame>
        <population>Safety population (those who received at least one dose of study medication)</population>
        <group_list>
          <group group_id="O1">
            <title>Pegylated Liposomal Doxorubicin</title>
            <description>Pegylated liposomal doxorubicin 50 mg/m^2 given every 4 weeks for up to 6 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pre-existing Allergic Conditions Who Experienced an IR</title>
          <description>Allergic conditions included food allergies, drug allergies, allergic rhinitis, histamine allergy, neurodermatitis, and chronic idiopathic urticaria.</description>
          <population>Safety population (those who received at least one dose of study medication)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Occurrences of Palmar-plantar Erythrodysesthesia (PPE)</title>
        <description>PPE was defined as a dermatological adverse event characterized by swelling, pain, edema, erythema, desquamation, that may have ultimately resulted in fissuring and ulceration, involving fingers, toes, palms, plantar aspects of the feet, and other pressure-sensitive areas of the skin.</description>
        <time_frame>Up to 24 weeks</time_frame>
        <population>Safety population (those who received at least one dose of study medication)</population>
        <group_list>
          <group group_id="O1">
            <title>Pegylated Liposomal Doxorubicin</title>
            <description>Pegylated liposomal doxorubicin 50 mg/m^2 given every 4 weeks for up to 6 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Occurrences of Palmar-plantar Erythrodysesthesia (PPE)</title>
          <description>PPE was defined as a dermatological adverse event characterized by swelling, pain, edema, erythema, desquamation, that may have ultimately resulted in fissuring and ulceration, involving fingers, toes, palms, plantar aspects of the feet, and other pressure-sensitive areas of the skin.</description>
          <population>Safety population (those who received at least one dose of study medication)</population>
          <units>Occurrences</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Times Premedications Were Given for Prevention of PPE</title>
        <description>Pre-medications given included oral dexamethasone, vitamin B6, and other not clearly defined medications.</description>
        <time_frame>Day 1 up to 24 weeks</time_frame>
        <population>Safety population (those who received at least one dose of study medication)</population>
        <group_list>
          <group group_id="O1">
            <title>Pegylated Liposomal Doxorubicin</title>
            <description>Pegylated liposomal doxorubicin 50 mg/m^2 given every 4 weeks for up to 6 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Times Premedications Were Given for Prevention of PPE</title>
          <description>Pre-medications given included oral dexamethasone, vitamin B6, and other not clearly defined medications.</description>
          <population>Safety population (those who received at least one dose of study medication)</population>
          <units>Number of times premedication was given</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oral dexamethasone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitamin B6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The safety data were from the safety population (those who received at least one dose of study medication).</desc>
      <group_list>
        <group group_id="E1">
          <title>Pegylated Liposomal Doxorubicin</title>
          <description>Pegylated liposomal doxorubicin 50 mg/m^2 given every 4 weeks for up to 6 cycles</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Cllinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

